Progress and future opportunities in the development of vaccines against atherosclerosis

Atherosclerosis represents a serious global health problem that demands new therapeutic and prophylactic interventions. Considering that atherosclerosis has autoimmune and inflammatory components, immunotherapy is a possible focus to treat this disease. Areas covered: Based on the analysis of the cu...

Full description

Saved in:
Bibliographic Details
Published inExpert review of vaccines Vol. 16; no. 4; pp. 337 - 350
Main Authors Govea-Alonso, Dania O, Beltrán-López, Josué, Salazar-González, Jorge A, Vargas-Morales, Juan, Rosales-Mendoza, Sergio
Format Journal Article
LanguageEnglish
Published England Taylor & Francis Group 01.04.2017
Subjects
Animals
Atherosclerosis - immunology
Atherosclerosis - prevention & control
auto-antigen
food-grade vaccines
Humans
humoral response
Immunotherapy - methods
inflammation
tolerance
Vaccines - chemistry
Vaccines - immunology
food-grade vaccines
inflammation
Auto-antigen
tolerance
humoral response
Online AccessGet full text

Cover

More Information
Summary:Atherosclerosis represents a serious global health problem that demands new therapeutic and prophylactic interventions. Considering that atherosclerosis has autoimmune and inflammatory components, immunotherapy is a possible focus to treat this disease. Areas covered: Based on the analysis of the current biomedical literature, this review describes the status on the development of vaccines against atherosclerosis. Several targets have been identified including sequences of apolipoprotein B100 (ApoB100), cholesteryl ester transfer protein (CETP), heat shock proteins (HSP), extracellular matrix proteins, T cell receptor β chain variable region 31 (TRBV31), the major outer membrane protein (MOMP), and the outer membrane protein 5 (Pomp5) from Chlamydia pneumoniae. Humoral and cellular immunities to these targets have been associated with therapeutic effects in murine models and humans. The evaluation of some candidates in clinical trials is ongoing. Expert commentary: New research paths based on the use of next generation vaccine production platforms are envisioned.
ISSN:1476-0584
1744-8395
DOI:10.1080/14760584.2017.1258309